Table 2 Univariable and multivariable Cox regression of overall survival in training and validation cohort
Statistics | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | ||
Age | |||||
< 65 | 234 (85.4%) | 1.0 | |||
> 65 | 40 (14.6%) | 0.8 (0.4, 1.6) | 0.458 | ||
Gender | |||||
Female | 44 (16.1%) | 1.0 | |||
Male | 230 (83.9%) | 1.5 (0.7, 3.1) | 0.291 | ||
Tumor number | |||||
Single | 235 (85.8%) | 1.0 | |||
Multiple | 39 (14.2%) | 1.3 (0.7, 2.4) | 0.486 | ||
Stage | |||||
I | 167 (60.9%) | 1.0 | |||
II | 82 (29.9%) | 2.0 (1.1, 3.7) | 0.026 | ||
III/IV | 25 (9.1%) | 3.6 (1.7, 7.6) | < 0.001 | ||
Adjuvant TACE | |||||
No | 177 (64.6%) | 1.0 | |||
Yes | 97 (35.4%) | 1.8 (1.1, 3.0) | 0.015 | ||
HBV | |||||
Negative | 32 (11.7%) | 1.0 | |||
Positive | 242 (88.3%) | 1.7 (0.7, 4.2) | 0.269 | ||
Tumor diameter | 5.4 + 4.1 | 1.2 (1.1, 1.2) | < 0.001 | 1.36 (1.24, 1.48) | < 0.0001 |
AFP | 4143.4 + 12,507.8 | 1.0 (1.0, 1.0) | 0.071 | ||
Microvascular invasion | |||||
No | 235 (91.1%) | 1.0 | |||
Yes | 23 (8.9%) | 3.0 (1.5, 6.0) | 0.002 | ||
Tumor differentiation | |||||
I/II | 191 (70.5%) | 1.0 | |||
III/IV | 80 (29.5%) | 2.3 (1.4, 3.8) | 0.001 | 11.27 (1.85, 68.53) | 0.008 |
9-gene signature | − 0.1 + 0.4 | 7.5 (5.0, 11.2) | < 0.001 | 2.94 (1.24, 6.99) | 0.014 |